The Next Generation Diabetes Drugs

The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance.


The highly favourable benefits of Glucox Biotech’ therapy is to decrease the critical risks and delay progression of the complications in Type 2 Diabetes patients by improving glycemic blood control.

Based on the company’s scientific excellence with a strong mission, Glucox Biotech aims to develop and produce the next generation safe and beneficial therapy for present and future diabetes suffers.

Pressrelease 1 May 2008


Successful screening of potential drug candidates

Glucox Biotech has together with Inovacia AB in Stockholm successfully
identified several novel small molecule inhibitors of ROS formation based on a project leading to selection of a drug candidates.

Primary hits, inhibiting induced ROS formation, have been confirmed by dose-response measurements and counter-assays including cell toxicity assays. Analysis of the medicinal chemistry potential of the series has resulted in few very promising chemical series amenable for lead generation.

Downlad a pdfDownload a pdf of the Pressrelease